Literature DB >> 35113268

Effect of methylpyrazoles and coumarin association on the growth of Gram-negative bacteria.

Florin Aonofriesei1.   

Abstract

One approach to overcome the antimicrobial resistance of many pathogens is to associate compounds with antimicrobial properties and obtain combinations superior compared to the effect of each compound. To identify a possible potentiating effect, we tested and analyzed the inhibitory effect of the combination of coumarin with two pyrazole derivatives, 1,1'-methandiylbis (3,5-dimethyl-1H-pyrazole (AM4) and 3,5-dimethyl-1H-pyrazol-1-yl) methanol 3,5-dimethyl-1-hydroxymethylpyrazol (SAM4). A clear synergistic effect was recorded when coumarin was associated with SAM4, in which case the Fractional Inhibitory Concentration Index (FICI) had a value equal to 0.468 for Citrobacter freundii, Proteus mirabilis, and E. coli. In the other cases, however, both the association between coumarin and AM4 and coumarin SAM4 had only an additive effect (FICI = 0.937-1.00). The bactericidal effect of the coumarin-pyrazole combination over time was better in all cases compared to the effect of the compounds used separately. The viability of the bacterial cells at sub-inhibitory concentrations of the tested compounds was variable, depending on both the type of compound and the bacterial strain.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Coumarin; Gram-negative bacteria; Pyrazoles; Synergistic effect

Mesh:

Substances:

Year:  2022        PMID: 35113268     DOI: 10.1007/s00203-022-02773-5

Source DB:  PubMed          Journal:  Arch Microbiol        ISSN: 0302-8933            Impact factor:   2.552


  11 in total

Review 1.  Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

Authors:  Ronald Domalaon; Temilolu Idowu; George G Zhanel; Frank Schweizer
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

2.  Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.

Authors:  Hao Liu; Zi-Li Ren; Wei Wang; Jie-Xiu Gong; Ming-Jie Chu; Quan-Wei Ma; Jie-Chun Wang; Xian-Hai Lv
Journal:  Eur J Med Chem       Date:  2018-07-26       Impact factor: 6.514

3.  The population impact of obesity, sedentary lifestyle, and tobacco and alcohol consumption on the prevalence of type 2 diabetes: Analysis of a health population survey in Chile, 2010.

Authors:  María P Bertoglia; Juan G Gormaz; Matías Libuy; Dérgica Sanhueza; Abraham Gajardo; Andrea Srur; Magdalena Wallbaum; Marcia Erazo
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

4.  Microbe Profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat.

Authors:  Stephen P Diggle; Marvin Whiteley
Journal:  Microbiology       Date:  2020-01       Impact factor: 2.777

5.  Effect of subinhibitory exposure to quaternary ammonium compounds on the ciprofloxacin susceptibility of Escherichia coli strains in animal husbandry.

Authors:  H Maertens; K Demeyere; K De Reu; J Dewulf; D Vanhauteghem; E Van Coillie; E Meyer
Journal:  BMC Microbiol       Date:  2020-06-11       Impact factor: 3.605

6.  Occurrence, identification, and antibiogram signatures of selected Enterobacteriaceae from Tsomo and Tyhume rivers in the Eastern Cape Province, Republic of South Africa.

Authors:  Folake Temitope Fadare; Martins Ajibade Adefisoye; Anthony Ifeanyi Okoh
Journal:  PLoS One       Date:  2020-12-07       Impact factor: 3.240

Review 7.  Genetics of Acquired Antibiotic Resistance Genes in Proteus spp.

Authors:  Delphine Girlich; Rémy A Bonnin; Laurent Dortet; Thierry Naas
Journal:  Front Microbiol       Date:  2020-02-21       Impact factor: 5.640

8.  Antimicrobial Resistance in Nosocomial Isolates of Gram-Negative Bacteria: Public Health Implications in the Latvian Context.

Authors:  Nityanand Jain; Inese Jansone; Tatjana Obidenova; Raimonds Simanis; Jānis Meisters; Dagnija Straupmane; Aigars Reinis
Journal:  Antibiotics (Basel)       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.